ReviewCurrent opinion in virology2014
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.
Review in Current opinion in virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.Frontiers in microbiology · 2025Review
- Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors.Archives of microbiology · 2024Article
- Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast.Microbial biotechnology · 2021Article
- Article
- The role of HCV proteins on treatment outcomes.Virology journal · 2015Review
- Review
- Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Virology journal · 2015Article
- The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication.Virology · 2015Article
- Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Viruses · 2014Review
- Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses.PLoS pathogens · 2014Review
- Editorial overview: antivirals and resistance: advances and challenges ahead.Current opinion in virology · 2014Article
- Virus-host interactomics: new insights and opportunities for antiviral drug discovery.Genome medicine · 2014Article
- Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The era of interferon-free antiviral treatments for hepatitis C virus infection has arrived. With increasing numbers of approved antivirals, evaluating all parameters that may influence response is necessary to choose optimal combinations for treatment success. Targeting NS5A has become integral in antiviral combinations in clinical development. Daclatasvir and ledipasvir belong to the NS5A inhibitor class, which directly target the NS5A protein. Alisporivir, a host-targeting antiviral, is a cyclophilin inhibitor that indirectly targets NS5A by blocking NS5A/cyclophilin A interaction. Resistance to daclatasvir and ledipasvir differs from alisporivir, with mutations arising in NS5A domains I and II, respectively. Combining these two classes acting on distinct NS5A domains represents an attractive strategy for potentially effective interferon-free treatments for chronic hepatitis C infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.